Publications

As indicated by our research policy, all projects are focused on generating publicly distributed reports or publications. While the following list is not comprehensive, it includes many of our most frequently requested reports and reprints. The Institute frequently collaborates with other institutions and organizations on research projects, and many of these publications were actually published by research partners or in peer-reviewed journals. The information page for each report will indicate how it can be acquired.

Zhang Y, Thamer M, Cotter D, Kaufman J, Hernan MA. Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States. Clin J Am Soc Nephrol. 2009 Mar;4(3):638-44. Epub 2009 Mar 4.

Thamer M, Hernan MA, Zhang Y, Cotter D, Petri M. Prednisone, lupus activity, and permanent organ damage. J Rheumatol. 2009 Mar;36(3):560-4. Epub 2009 Feb 4.

Cotter DJ, Thamer M, Zhang Y. Relative mortality and epoetin alpha dose in hemodialysis patients. Am J Kidney Dis. 2008 May;51(5):865

Cotter D, Zhang Y, THamer M, Kaufman J, Hernan MA. The effect of epoetin dose on hematocrit. Kidney Int. 2008 Feb;73(3):347-53. Epub 2007 Nov 14.

Thamer M, Zhang Y Kaufman J, Cotter D, Hernan MA. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis: the authors respond. Am J Kidney Dis. 2007 Oct;50(4):538-41.

Thamer M, Zhang Y, Kaufman J, Cotter D, Dong F, Hernan MA. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA. 2007 Apr 18;297(15):1667-74.

Cotter D, Thamer M, Narasimhan K, Zhang Y, Bullock K. Translating epoetin research into practice: the role of government and the use of scientific evidence. ealth Aff (Millwood). 2006 Sep-Oct;25(5):1249-59.

Thamer M, Zhang Y, Kaufman J, Stefanik K, Cotter DJ. Factors influencing route of administration for epoetin treatment among hemodialysis patients in the United States. Am J Kidney Dis. 2006 Jul;48(1):77-87.

Cotter DJ, Stefanik K, Zhang Y, Thamer M, Scharfstein D, Kaufman J. Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. J Clin Epidemiol. 2004 Oct;57(10):1086-95.

Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ. Epoetin requirements predict mortality in hemodialysis patients. American Journal of Kidney Diseases. 2004

Cotter DJ, Stefanik K, Zhang Y, Thamer M, Scharfstein D, Kaufman J. Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. Journal of Clinical Epidemiology. 2004

Cotter DJ, Stefanik K, Zhang Y, Thamer M. Improved survival with higher hematocrits: Where is the evidence? Semin Dial 2004;17:181-183.

Thamer M, Richard CM, Klinkmann J, Ivanovich P, Lang G, Cotter DJ. Use of clinical guidelines for treatment of anemia among hemodialysis patients. Artificial Organs 2000;24(2):91-94.

Cotter DJ, Perry S, Thamer M. Technology Assessment at the National Level in the US. Surg Technol Int. 2000;8:45-48

Perry S, Thamer M. Medical innovation and the critical role of health technology assessment. JAMA 1999;282:1869-72.

Ray NF, Baraniuk JN, Thamer M, et al. Healthcare expenditures for sinusitis in 1996: Contributions of asthma, rhinitis, and other airway disorders. Journal of Allergy and Clinical Immunology 1999;103:408-414.

Ray NF, Baraniuk JN, Thamer M, Rinehart CS, Gergen PJ, Kaliner M, Josephs S, Pung YH. Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses. Journal of Allergy and Clinical Immunology 1999;103:401-407.

Thamer M, Henderson SC, Ray NF, Rinehart CS, Greer JW, Danovitch GM. Unequal access to cadaveric kidney transplantation in California based on insurance status. Health Services Research 1999;34:879-900.

Thamer M, Ray NF, Taylor T. Association between anti-hypertensive use and hypoglycemia: A case-control study of diabetic users of insulin or sulfonylureas. Clinical Therapeutics 1999;21:1387-1400.

Gardner E, Murtaugh CM, Ray NF, Thamer M. The cost of health care services for disabled Medicaid recipients with neurological disorders: Implications for managed care. American Journal of Managed Care 1999;5:1417-1425.

Ray NF, Denton W, Thamer M, Henderson SC, Perry S. Abdominal adhesions: inpatient care and expenditures in the United States. Journal of the American College of Surgeons 1998;186:1-9.

Ray NF, Thamer M, Fadillioglu B, Gergen PJ. Race, income, urbanicity and asthma hospitalizations in California: Small area analysis. Chest 1998;113:1277-84.

Kimmel PL, Thamer M, Richard CM, Ray NF. Psychiatric illness in patients with end-stage renal disease. American Journal of Medicine 1998;105:214-21.

Cotter DJ, Thamer M, Kimmel PL, Sadler JH. Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990 - 1996. Kidney International 1998;54:2129-39.

Perry S, Thamer M. Health technology assessment: Decentralized and fragmented in the United States compared to other countries. Health Policy 1998;42:269-90.

Thamer M, Ray NF, Henderson SC, Rinehart CS, Sherman CR, Ferguson JH. Influence of the NIH Consensus Conference on H. Pylori on physician prescribing among a Medicaid population. Medical Care 1998;36:646-60.

Ray NF, Thamer M, Henderson SC. Adoption of new pharmacotherapeutic regimens: Analysis of physician prescribing for peptic ulcer disease. Drug Information Journal 1998;32:1119-31.

Thamer M, Chan JK, Ray NF, Vassalotti JA, Kimmel PL. Drug use concomitant with cyclosporine immunosuppressive therapy for three years after renal transplantation. American Journal of Kidney Diseases 1998;31:283-92.

Thamer M, Brennan N, Semansky R. A cross-national comparison of "orphan" drug policies: Implications for the U.S. Orphan Drug Act. Journal of Health Politics, Policy and Law 1998;23:265-90.

Ray NF, Thamer M, Gardner E, Chan JK. Economic consequences of diabetes mellitus in the United States in 1997. Report of the American Diabetes Association. Diabetes Care 1998;21:296-308.

Thamer M, Rinehart CS. Private and public health insurance among U.S. foreign-born residents: Implications of the 1996 Welfare Reform Law. Ethnicity & Health 1998;3:19-29.

Thamer M, Richard C, Casebeer AW, Ray NF. Health insurance coverage of foreign-born residents living in the Unites States: Impact of race, ethnicity and length of residence. American Journal of Public Health 1997;87:96-102.

Thamer M, Fitzpatrick KJ, Perry S. Medical and surgical supply costs: Case study of a costly "low-cost" technology. International Journal of Technology Assessment in Health Care 1997;13:528-38.

Perry S, Gardner E, Thamer M. Status of health technology assessment worldwide: Results of an international survey. International Journal of Technology Assessment in Health Care 1997;13:81-98.

Ray NF, Chan JK, Thamer M, Melton LJ III. Medical expenditures for osteoporotic fractures in the United States in 1995. Journal of Bone and Mineral Research 1997;12:24-35.

Melton LJ III, Thamer M, Ray NF, Chan JK and the National Osteoporosis Foundation Expert Panel on Fractures. Fractures attributable to osteoporosis. Journal of Bone and Mineral Research 1997;12:16-23.

Ray NF, Thamer M, Taylor T, Fehrenback SN, Ratner R. Hospitalization and expenditures for the treatment of general medical conditions among the U.S. diabetic population. Journal of Clinical Endocrinology and Metabolism 1996;81:3671-79.

Thamer M, Richard C, Ray NF, Greer JW, Cotter DJ, Pearson BC. The effect of insurance status on use of recombinant erythropoietin therapy among End-Stage Renal Disease patients in three states. American Journal of Kidney Diseases 1996;28:235-49.

Thamer M, Ray NF, Fehrenback SN, Richard C, Kimmel PL. Relative risk and economic consequences of inpatient care among renal failure patients. Journal of the American Society of Nephrology 1996;7:751-62.

Thamer M, Ray NF, Richard C, Greer JW, Pearson BC, Cotter DJ. Excluded from universal coverage: End-Stage Renal Disease patients not covered by Medicare. Health Care Financing Review 1995;17:123-46.

National Health Service and Practice Patterns Survey Report on:

First-Year Report on Tissue-type Plasminogen Activator For Coronary Artery Thrombosis Operating Costs, Medicare Payments and Utilization Rates - July 1990

Economic Impact of Proposed FY 1991 Medicare Payment Rate Changes For Major Cardiovascular Procedures - July 1990

First-Year Report on Decubitus Ulcers Incidence Rates, Treatment Costs and Medicare Payments - May 1990

First-Year Report on Percutaneous Transluminal Coronary Angioplasty Operating Costs, Medicare Payments and Utilization Rates - December 1989

First-Year Report on Adult Liver Transplantation Operating Costs, Medicare Payments and Utilization Rates - November 1988

Inpatient Hemodialysis Operating Costs, Medicare Payments and Utilization Rates - September 1989

Second-Year Report on Inpatient Magnetic Resonance Imaging Operating Costs, Medicare Payments and Utilization Rates - August 1989

First-Year Report on Automatic Implantable Cardiovascular-Defibrillators Operating Costs, Medicare Payments and Utilization Rates - May 1989

The Rational/Irrational Quotient of the Diffusion of Heart Transplant Centers in the United States - September 1988

Second-Year Report on Heart Transplant Operating Costs, Medicare Payments and Utilization Rates - August 1988

Non-invasive Transesophageal Cardiac Output Monitoring - April 1988

Outpatient Magnetic Resonance Imaging Operating and Capital Costs, Medicare Payments and Utilization Rates Phase I - November 1987

Outpatient Extracorporeal Shock-wave Lithotripsy Operating and Capital Costs, Medicare Payments and Utilization rates Phase I - October 1987

Percutaneous Lithotripsy Operating Costs, Medicare Payments and Utilization Rates - April 1987

Heart Transplantation Operating costs, Medicare Payments and Utilization Rates - November 1986

Magnetic Resonance Imaging Capital and Operating Costs, Medicare Payments and Utilization Rates - October 1986

Extracorporeal Shockwave Lithotripsy Operating Costs Medicare Payments and Utilization Rates - April 1986

The Impact of Magnetic Resonance Imaging on Computed Tomography use; Market Dynamics in the United States Imaging Industry - MRI in the Shadow of CT - January 1998

Special Reports

Perry S, Thamer M, Gardner E. Rational Use of Health Technologies: Mexico & U.S., MTPPI, 1996

Jenny C, Taylor RJ, Cooper M. Diagnostic Imaging & Child Abuse: Technologies, Practices & Guidelines, MTPPI, 1996

[No Listed Authors]Implications of NAFTA for Trade in Health Care Technologies, MTPPI, 1994

[No Listed Authors] Health Care Technology in Developing Countries, MTPPI, 1994

[No Listed Authors] Direct and Indirect Cost of Diabetes in the U.S. American Diabtes Association, MTPPI, 1993

DRAFT MINUTES OF THE OCTOBER 21, 1999 PLANNING MEETING: ETHICAL AND REGULATORY ISSUES RELATED TO COMPENSATION TO PRACTICING PHYSICIANS FOR CLINICAL TRIALS

Practice Guidelines: Role of Economics & Physicians